An expanded ACPA repertoire was suggested by Giles et al. as a distinct feature of antibody associations with ILD, e.g. expanded ACPA specificities were most strongly associated with features of fibrosis, while anti-CCP2 level indicated ILD outcome [7]. This evidence concerns the gene PRTN3 and interstitial lung disease.